Cargando…

Rational Control of Molecular Properties Is Mandatory to Exploit the Potential of PROTACs as Oral Drugs

[Image: see text] To obtain new oral drugs in the beyond rule of five space, PROTACs among others, molecular properties should be optimized in early drug discovery. Degraders call for design strategies which focus on intramolecular interaction and chameleonicity. In parallel, tailored revalidation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ermondi, Giuseppe, Garcia Jimenez, Diego, Rossi Sebastiano, Matteo, Caron, Giulia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274089/ https://www.ncbi.nlm.nih.gov/pubmed/34262642 http://dx.doi.org/10.1021/acsmedchemlett.1c00298

Ejemplares similares

Are we ready to design oral PROTACs®?
por: Jimenez, Diego Garcia, et al.
Publicado: (2021)

The Quest for Oral PROTAC drugs: Evaluating the Weaknesses of the Screening Pipeline
por: Apprato, Giulia, et al.
Publicado: (2023)

Designing Soluble PROTACs: Strategies and Preliminary Guidelines
por: García Jiménez, Diego, et al.
Publicado: (2022)

PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery
por: Ermondi, Giuseppe, et al.
Publicado: (2021)

Refinement of Computational Access to Molecular Physicochemical Properties: From Ro5 to bRo5
por: Rossi Sebastiano, Matteo, et al.
Publicado: (2022)

Conformational Sampling Deciphers the Chameleonic Properties of a VHL-Based Degrader
por: Ermondi, Giuseppe, et al.
Publicado: (2023)

In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor
por: Apprato, Giulia, et al.
Publicado: (2023)

Chamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-of-5 Drugs
por: Garcia Jimenez, Diego, et al.
Publicado: (2023)

Rational Design and Synthesis of HSF1-PROTACs for Anticancer Drug Development
por: Sharma, Chiranjeev, et al.
Publicado: (2022)

Personalized Treatment for Infantile Ascending Hereditary Spastic Paralysis Based on In Silico Strategies
por: Rossi Sebastiano, Matteo, et al.
Publicado: (2022)

Novel approaches for the rational design of PROTAC linkers
por: Zagidullin, Almaz, et al.
Publicado: (2020)

Linker-Dependent Folding Rationalizes PROTAC Cell Permeability
por: Poongavanam, Vasanthanathan, et al.
Publicado: (2022)

Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders
por: Hornberger, Keith R., et al.
Publicado: (2023)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

Modeling ErbB2-p130Cas interaction to design new potential anticancer agents
por: Costamagna, Andrea, et al.
Publicado: (2019)

Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents
por: Costamagna, Andrea, et al.
Publicado: (2019)

PROTAC: targeted drug strategy. Principles and limitations
por: Koroleva, O. A., et al.
Publicado: (2022)

Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
por: Ishikawa, Minoru, et al.
Publicado: (2020)

Clinical considerations for the design of PROTACs in cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2022)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design
por: Palomba, Tommaso, et al.
Publicado: (2022)

The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
por: Poso, Antti
Publicado: (2021)

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
por: Burke, Matthew R., et al.
Publicado: (2022)

Recent Advances in PROTACs for Drug Targeted Protein Research
por: Yao, Tingting, et al.
Publicado: (2022)

An overview of PROTACs: a promising drug discovery paradigm
por: Liu, Zi, et al.
Publicado: (2022)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

Solubility prediction in the bRo5 chemical space: where are we right now?
por: Ermondi, Giuseppe, et al.
Publicado: (2020)

Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs
por: Kou, Ponien, et al.
Publicado: (2023)

Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs
por: Pöstges, Florian, et al.
Publicado: (2023)

Editorial: Application of PROTACs as a Novel Strategy for Drug Discovery
por: Ibrahim, Hany S., et al.
Publicado: (2021)

PROTACs: A novel strategy for cancer drug discovery and development
por: Han, Xin, et al.
Publicado: (2023)

PROTACs: The Future of Leukemia Therapeutics
por: Anwar, Zubair, et al.
Publicado: (2022)

PROTACs in the Management of Prostate Cancer
por: Yedla, Poornachandra, et al.
Publicado: (2023)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

Managing Experimental 3D Structures in the Beyond‐Rule‐of‐5 Chemical Space: The Case of Rifampicin
por: Ermondi, Giuseppe, et al.
Publicado: (2021)

Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
por: Pei, Haixiang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gkt1m8db8r50midm2b5ck3nc6u